Proteo Inc Watch

from 8-K 5 pages Proteo, Inc. Common Stock Purchase Agreement

from 8-K 5 pages Proteo, Inc. Common Stock Purchase Agreement

from 10-Q 1 page Proteo, Inc. Att: Chief Executive Officer Mr. Oliver Wiedow 2102 Business Center Drive Irvine, Ca 92612 USA Re: Elafin License Agreement 1. the Parties Herewith Agree That Licensor Defers to November 15, 2021 the Total Amount of 570,000 Euros Payable by Licensee, Which Otherwise Would Be Due on November 15, 2020 (Hereinafter the “Deferral”). 2. in the Event That the Company's Financial Condition Improves, the Parties Would Endeavor to Enter in Good Faith Negotiations to Accelerate the Payments

from 10-Q 1 page Prof. Dr. Med. Oliver Wiedow, Forstweg 55, D-24105 Kiel, Germany

from 8-K 8 pages Proteo, Inc. Preferred Stock Purchase Agreement

from 8-K 6 pages Proteo, Inc. Common Stock Purchase Agreement

from 10-Q 1 page Prof. Dr. Med. Oliver Wiedow, Forstweg 55, D-24105 Kiel, Germany

from 8-K 7 pages Proteo, Inc. Preferred Stock Purchase Agreement

from 8-K 1 page Letter of Intent - Silverscreen Associates Gmbh Will Be Renamed Into Cfi Corporate Finance and Innovation Gmbh; - The Company Will in Whole Be Taken Over by a Group of Investors, Who Are Committed to the Plans Set Forth Below; - I Will Be Substituted as Managing Director by Jork Von Reden; - The Office of the Company Will Be Moved to Normannenweg, Berlin

from 10-Q 1 page Prof. Dr. Med. Oliver Wiedow Forstweg 55 D-24105 Kiel Germany

from 8-K 10 pages Confidential Information Has Been Omitted From Portions of This Document, Indicated by [*], and Filed Separately With the Securities and Exchange Commission. Confidential Treatment Has Been Requested With Respect to This Omitted Information. Agreement

from 10-K 8 pages Proteo, Inc. Preferred Stock Purchase Agreement

from 10-K 1 page Summary of Amendments to Ms. Birge Bargmann’s Employment Agreement Dated May 27, 2011, With Proteo Biotech AG Dated April 2, 2013 and on November 14, 2013

from 10-K 1 page Proteo, Inc. Att: Chief Executive Officer Ms. Birge Bargmann 2102 Business Center Drive Irvine, Ca 92612 USA Re: Elafin License Agreement

from 10-K 1 page Kiel, on February 6, 2012

from 10-Q 1 page Proteo, Inc. Att: Chief Executive Officer Ms. Birge Bargmann 2102 Business Center Drive Irvine, Ca 92612 USA Re: Elafin License Agreement 1. the Parties Herewith Agree That Licensor Defers to December 31st, 2011 the Instalment Payable by Licensee in the Amount of 60,000 Euros, Which Otherwise Would Be Due on December 31st, 2010 (Hereinafter the “Deferral”). 2. Neither the Waiver Nor the Deferral Under Section 1 Hereof, Would Constitute a Waiver of or Estoppel to Licensor‘s Rights to Already Existing or Future Pay­ment Obligations Under the License Agreement. /S/ Oliver Wiedow Prof. Dr. Med. Oliver Wiedow We Agree to the Foregoing Proteo, Inc., on July 28, 2011 /S/ Birge Bargmann Birge Bargmann, Chief Executive Officer

from 10-Q 5 pages Contract for an Atypical Silent Partnership

from 10-Q 1 page Summary of Material Terms of License Agreement

from 10-Q 6 pages License Agreement

from 10-Q 11 pages Forbearance Agreement and General Release